Immunotherapy News and Research

Latest Immunotherapy News and Research

Compugen drug candidate prevents autoimmune type I diabetes in animal model

Compugen Ltd., announced today that CGEN-15001, an Fc fusion protein drug candidate derived from a novel immune checkpoint protein discovered by Compugen, has been shown to be highly efficient in preventing the development of disease in a well-accepted animal model of autoimmune type I diabetes, known also as juvenile diabetes.

9 Oct 2013

Molecular Templates secures $8.5M series C financing plus $10.6M grant from CPRIT

Molecular Templates, Inc., a biopharmaceutical company focused on the discovery and development of a new class of biologic therapeutics, announced today that it recently secured an $8.5M series C financing led by Excel Venture Management. Santé Ventures, an existing investor, also participated in the round.

9 Oct 2013

Oncosec Medical reports encouraging results from combination study on aggressive melanoma

OncoSec Medical Inc., a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors, has announced positive preliminary animal data demonstrating the benefits of combining the company's ImmunoPulse with anti-CTLA4 and anti-PD1 antibodies.

9 Oct 2013

New therapeutic targets and drugs may benefit people with leukemia

An Indiana University cancer researcher and his colleagues have discovered new therapeutic targets and drugs that may someday benefit people with certain types of leukemia or blood cancer.

5 Oct 2013

Hypertension Drug May Aid Cancer Treatment

...

2 Oct 2013

New research shows no increased danger for egg allergic children who take flu shots

All children should have flu shots, even if they have an egg allergy, and it's now safe to get them without special precautions. This finding is from the latest update on the safety of the flu vaccine for allergic patients, published in the October issue of the Annals of Allergy, Asthma and Immunology, the official journal of the American College of Allergy, Asthma and Immunology.

2 Oct 2013

Merck & Co. Axes 8,500 In R&D Restructuring

...

1 Oct 2013

Merck & Co. Axes 8,500 In R&D Restructuring

...

1 Oct 2013

Circassia reports positive results from phase II clinical study of ToleroMune grass allergy treatment

Circassia Ltd, a specialty biopharmaceutical company focused on developing world-class immunotherapies, today announced successful results from a large phase II clinical study of its ToleroMune® grass allergy treatment (Grass-Synthetic Peptide Immuno-Regulatory Epitope [Grass-SPIRE])

1 Oct 2013

Study suggests relationship between smoking history, response to inhibiting PD-L1/PD-1 pathway

New results from a trial of an antibody that helps the immune system to recognise and attack cancer cells have shown particularly encouraging responses in patients who are smokers or former smokers.

30 Sep 2013

AMGEN announces additional results from talimogene laherparepvec Phase 3 trial

AMGEN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).

30 Sep 2013

First Phase II study: Everolimus drug slows spread of advanced papillary kidney cancer

The first Phase II study to investigate the use of the anti-cancer drug, everolimus, for the initial treatment of advanced papillary kidney cancer has shown that it is successful in slowing or preventing the spread of the disease, according to research to be presented today (Sunday) at the 2013 European Cancer Congress.

29 Sep 2013

SBIR Awards Etubics $1.5M To Manufacture Breast Cancer Immunotherapy

...

27 Sep 2013

Inflammatory marker may highlight aggressive RCC treatment need

Patients with metastatic renal cell carcinoma who have high preoperative levels of the inflammatory marker C-reactive protein may need intensive multimodal treatment to optimize their survival, say researchers.

24 Sep 2013

Tips for reducing allergens in yards

Prepping your yard this fall can give you a head start on spring landscaping, but it can also mean suffering from seasonal allergies seasonal allergies. Ragweed pollen and lingering mold can create double the symptoms for some allergy sufferers.

18 Sep 2013

LSDF announces Proof of Concept grants to speed up promising health-related technologies

For-profit and non-profit organizations in Washington state will receive $1.25M in Proof of Concept grant funding to accelerate the translation of promising health-related technologies from concept to commercialization, the Life Sciences Discovery Fund (LSDF) announced today.

18 Sep 2013

FDA grants Breakthrough Therapy designation to Boehringer Ingelheim's volasertib

Boehringer Ingelheim Pharmaceuticals, Inc. today announced the FDA has granted Breakthrough Therapy designation to volasertib, an investigational inhibitor of polo-like kinase, being evaluated for the treatment of patients aged 65 or older with previously untreated acute myeloid leukemia, ineligible for intensive remission induction therapy.

17 Sep 2013

Dendreon Gets Green Light In Europe

...

17 Sep 2013

Dendreon Gets Greenlight In Europe

...

17 Sep 2013

New method to target, eliminate cancer-supporting macrophages in mouse tumors

When a person has cancer, some of the cells in his or her body have changed and are growing uncontrollably. Most cancer drugs try to treat the disease by killing those fast-growing cells, but another approach called immunotherapy tries to stimulate a person's own immune system to attack the cancer itself.

17 Sep 2013

Immunotherapy News and Research

Latest Immunotherapy News and Research

Compugen drug candidate prevents autoimmune type I diabetes in animal model

Molecular Templates secures $8.5M series C financing plus $10.6M grant from CPRIT

Oncosec Medical reports encouraging results from combination study on aggressive melanoma

New therapeutic targets and drugs may benefit people with leukemia

Hypertension Drug May Aid Cancer Treatment

New research shows no increased danger for egg allergic children who take flu shots

Merck & Co. Axes 8,500 In R&D Restructuring

Merck & Co. Axes 8,500 In R&D Restructuring

Circassia reports positive results from phase II clinical study of ToleroMune grass allergy treatment

Study suggests relationship between smoking history, response to inhibiting PD-L1/PD-1 pathway

AMGEN announces additional results from talimogene laherparepvec Phase 3 trial

First Phase II study: Everolimus drug slows spread of advanced papillary kidney cancer

SBIR Awards Etubics $1.5M To Manufacture Breast Cancer Immunotherapy

Inflammatory marker may highlight aggressive RCC treatment need

Tips for reducing allergens in yards

LSDF announces Proof of Concept grants to speed up promising health-related technologies

FDA grants Breakthrough Therapy designation to Boehringer Ingelheim's volasertib

Dendreon Gets Green Light In Europe

Dendreon Gets Greenlight In Europe

New method to target, eliminate cancer-supporting macrophages in mouse tumors

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Immunotherapy News and Research

Latest Immunotherapy News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in